髓细胞衍生外体通过自身隐性途径减少抗癌药物诱导的肌肉毒性
Woojin Lee1, Euijin Sohn2, Sang Bum Kim3
1College of Pharmacy, Sahmyook University, Seoul, Republic of Korea 01795. 97woo@naver.com.
Cellular and molecular biology (Noisy-le-Grand, France)
|November 28, 2024
概括
肌肉干细胞衍生外体 (MDEs) 显示出对抗癌症缓解症的前景. 这些外体增强肌肉细胞的存活率,并可能减轻化疗药物诱导的肌肉毒性,提供潜在的新治疗途径.
科学领域:
- 生物医学科学 生物医学科学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- 癌症缓解症,标志着肌肉损失,影响高达80%的癌症患者,特别是那些有消化系统恶性瘤的人.
- 抗癌药物可以诱导肌肉毒性,导致缓冲症,有效治疗方法有限.
- 肌肉干细胞在肌肉再生中发挥作用,这表明它们的衍生外体可能具有治疗作用.
研究的目的:
- 为了研究肌肉干细胞衍生的外体的治疗潜力 (MDEs) 缓解癌症缓解.
- 检查MDEs在减轻抗癌药物诱导的肌肉毒性的作用.
- 描述MDEs并确认它们在增强肌肉细胞活力的作用.
主要方法:
- 在血清饥饿条件下,从神经细胞中分离出外体,并以大小和蛋白质标记物进行表征.
- 电子显微镜被用来确认外体结构.
- 评估了MDEs对髓细胞活力和细胞循环的影响,以及它们保护细胞免受氧沙和多克索鲁比诱导的细胞死亡的能力.
主要成果:
- 具有特征的外体细胞 (平均尺寸为113纳米) 含有典型的外体细胞标记物,并通过增加肌细胞活力来证实了对膜功能.
- MDEs增强了肌肉细胞存活率和整体细胞活力,特别是在血清饥饿条件下.
- MDEs显示对低度的氧沙丁和多克索鲁比辛有保护作用,这表明它在减少抗癌药物诱导的肌肉细胞损伤方面发挥了作用.
结论:
- 肌细胞衍生外体 (MDEs) 具有增强肌肉细胞生存和活力的能力.
- 通过减少某些抗癌药物诱导的肌肉细胞损伤,MDEs显示出控制癌症缓解症的潜力.
- 对MDEs的进一步研究可能会导致新的治疗策略来管理与化疗相关的缓解症.
相关概念视频
Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


